Examining the impact of real-world evidence on medical product development : proceedings of a workshop series / Erin Hammers Forstag, Benjamin Kahn, Amanda Wagner Gee, and Carolyn Shore, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division, the National Academies of Sciences, Engineering, Medicine.

"Randomized controlled trials (RCTs) have traditionally served as the gold standard for generating evidence about medical interventions. However, RCTs have inherent limitations and may not reflect the use of medical products in the real world. Additionally, RCTs are expensive, time consuming, and ca...

Full description

Bibliographic Details
Main Author: Forstag, Erin Hammers (rapporteur.)
Corporate Authors: National Academies of Sciences, Engineering, and Medicine (U.S.). Forum on Drug Discovery, Development, and Translation (Issuing body)
Examining the Impact of Real-World Evidence on Medical Product Development (Workshop)
Other Authors: Kahn, Benjamin (rapporteur.)
Gee, Amanda Wagner (rapporteur.)
Shore, Carolyn (rapporteur.)
Language:English
Published: Washington, DC : the National Academies Press, [2019]
Subjects:
Genre:
Physical Description:xxi, 207 pages : illustrations ; 23 cm
Format: Conference Proceeding Book

MARC

LEADER 00000cam a2200000Ki 4500
001 in00005965351
003 OCoLC
005 20231221200714.6
008 190318t20192019dcua b 000 0 eng d
020 |a 030948829X 
020 |a 9780309488297 
035 |a (OCoLC)1089854782 
040 |a YDX  |b eng  |e rda  |c YDX  |d EEM  |d UtOrBLW 
049 |a EEMR 
050 4 |a R723.7  |b .F67 2019 
100 1 |a Forstag, Erin Hammers,  |e rapporteur.  |0 http://id.loc.gov/authorities/names/no2009099563 
245 1 0 |a Examining the impact of real-world evidence on medical product development :  |b proceedings of a workshop series / Erin Hammers Forstag, Benjamin Kahn, Amanda Wagner Gee, and Carolyn Shore, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division, the National Academies of Sciences, Engineering, Medicine. 
264 1 |a Washington, DC :  |b the National Academies Press,  |c [2019] 
264 4 |c ©2019 
300 |a xxi, 207 pages :  |b illustrations ;  |c 23 cm 
336 |a text  |b txt  |2 rdacontent 
337 |a unmediated  |b n  |2 rdamedia 
338 |a volume  |b nc  |2 rdacarrier 
504 |a Includes bibliographical references (pages 177-180). 
505 0 |a Introduction -- Perspectives on real-world evidence -- Learning from success -- Barriers and disincentives to the use of real-world evidence and real-world data -- Getting unstuck : mythbusting the current system -- When is a real-world data element fit for assessment of eligibility, treatment exposure, or outcomes? -- How tightly should investigators attempt to control or restrict treatment quality in a pragmatic or real-world trial? -- Obscuring intervention allocation in trials to generate real-world evidence : why, who, and how? -- Gaining confidence in observational comparisons -- Looking ahead -- References -- Appendixes 
520 |a "Randomized controlled trials (RCTs) have traditionally served as the gold standard for generating evidence about medical interventions. However, RCTs have inherent limitations and may not reflect the use of medical products in the real world. Additionally, RCTs are expensive, time consuming, and cannot answer all questions about a product or intervention. Evidence generated from real-world use, such as real-world evidence (RWE) may provide valuable information, alongside RCTs, to inform medical product decision making. To explore the potential for using RWE in medical product decision making, the National Academies of Sciences, Engineering, and Medicine planned a three-part workshop series. The series was designed to examine the current system of evidence generation and its limitations, to identify when and why RWE may be an appropriate type of evidence on which to base decisions, to learn from successful initiatives that have incorporated RWE, and to describe barriers that prevent RWE from being used to its full potential. This publication summarizes the discussions from the entire workshop series"--Publisher's description 
650 0 |a Drugs  |x Testing  |v Congresses.  |0 http://id.loc.gov/authorities/subjects/sh2009123918 
650 0 |a Evidence-based medicine  |x Decision making  |v Congresses.  |0 http://id.loc.gov/authorities/subjects/sh97007984 
650 0 |a Medical instruments and apparatus  |v Congresses.  |0 http://id.loc.gov/authorities/subjects/sh2010101220 
700 1 |a Kahn, Benjamin,  |e rapporteur.  |0 http://id.loc.gov/authorities/names/n2017180345 
700 1 |a Gee, Amanda Wagner,  |e rapporteur.  |0 http://id.loc.gov/authorities/names/no2008155685 
700 1 |a Shore, Carolyn,  |e rapporteur.  |0 http://id.loc.gov/authorities/names/n2019182978 
710 2 |a National Academies of Sciences, Engineering, and Medicine (U.S.).  |b Forum on Drug Discovery, Development, and Translation,  |e issuing body.  |0 http://id.loc.gov/authorities/names/n2016189921 
711 2 |a Examining the Impact of Real-World Evidence on Medical Product Development (Workshop),  |j issuing body.  |0 http://id.loc.gov/authorities/names/n2019183638 
907 |y .b131270175  |b 190502  |c 190425 
998 |a mn  |b 190425  |c m  |d a  |e -  |f eng  |g dcu  |h 0  |i 2 
994 |a C0  |b EEM 
999 f f |i 16b31eb3-b6a5-5387-926b-3d6991714281  |s 1a3feff7-3d2b-5387-9dcb-13546d2121e3  |t 0 
952 f f |p Can Circulate  |a Michigan State University-Library of Michigan  |b Michigan State University  |c MSU Main Library  |d MSU Main Library  |t 0  |e R723.7 .F67 2019  |h Library of Congress classification  |i Printed Material  |m 31293036550279  |n 1